How does mass spectrometry help screen newborns for metabolic diseases?

Mass spectrometry (MS) is a vital tool for newborn screening, enabling the early detection of inborn errors of metabolism—rare genetic disorders that can cause severe developmental delays or brain damage if left untreated.12

The screening process typically involves the following steps:

• Sample Collection: A small droplet of blood is collected from a newborn, usually via a heel stick, and blotted onto an absorbent paper card.1
• Extraction and Analysis: Metabolites are extracted from these dried blood spots and analyzed using MS. This technology is highly valued for its impressive sensitivity and specificity, allowing laboratories to screen for multiple metabolic disorders simultaneously from a single sample.123
• Clinical Application: By identifying abnormal concentrations of specific metabolites—such as the elevated phenylalanine levels associated with phenylketonuria—clinicians can intervene early.12

Early detection through MS-based screening is critical, as it often allows for dietary therapies or other medical interventions that can prevent or attenuate neurological injury and support normal development.2